Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease
Bernard Hanseeuw(Cliniques Universitaires Saint-Luc), Keith A. Johnson(Brigham and Women's Hospital), Aaron P. Schultz(Harvard University), Jorge Sepulcre(Harvard University), J. Alex Becker(Jacobson Holman (United States)), Willem Huijbers(Massachusetts General Hospital), Rebecca Amariglio(Brigham and Women's Hospital), Rebecca A. Betensky(Harvard University), Adrian Ivanoiu, Danielle M. Cosio(Gordon Center for Medical Imaging), Rachel F. Buckley(Harvard University), Yakeel T. Quiroz(Harvard University), Gad A. Marshall, Trey Hedden(Harvard University), Kathryn V. Papp(Brigham and Women's Hospital), Dorene M. Rentz(Brigham and Women's Hospital), Ilse Dewachter(Hasselt University), Elizabeth C. Mormino(Allen Institute for Brain Science), Jasmeer P. Chhatwal(Harvard University), Heidi I.L. Jacobs(Harvard University), Michelle E. Farrell(Harvard University), Reisa A. Sperling(Harvard University)
Cited by 876
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k